Skip to content
10-Q

Quarterly Report

ANTARES PHARMA, INC.

0001016169-22-000044

← back to feed
Filed
May 10, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 5, 2022 170.85M sh
Shares Diluted Q1 2022 · Mar 31, 2022 170.1M sh
Shares Diluted Q1 2022 · Mar 31, 2021 174.91M sh
Capex Q1 2022 · Mar 31, 2022 $81K
Capex Q1 2022 · Mar 31, 2021 $1.18M
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$4.88M
Operating Cash Flow Q1 2022 · Mar 31, 2021 $1.98M
Long Term Debt Q1 2022 · Mar 31, 2022 $17.89M
Long Term Debt Q1 2022 · Dec 31, 2021 $18.24M
Short Term Debt Q1 2022 · Mar 31, 2022 $1.5M
Short Term Debt Q1 2022 · Dec 31, 2021 $1.5M
Short Term Investments Q1 2022 · Mar 31, 2022 $498K
Short Term Investments Q1 2022 · Dec 31, 2021 $1.25M
Cash And Equivalents Q1 2022 · Mar 31, 2022 $61.72M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $65.91M
Stockholders Equity Q1 2022 · Mar 31, 2022 $175.77M
Stockholders Equity Q1 2022 · Dec 31, 2021 $175.76M
Stockholders Equity Q1 2022 · Mar 31, 2021 $126.23M
Stockholders Equity Q1 2022 · Dec 31, 2020 $119.12M
Current Liabilities Q1 2022 · Mar 31, 2022 $55.73M
Current Liabilities Q1 2022 · Dec 31, 2021 $58.93M
Total Liabilities Q1 2022 · Mar 31, 2022 $79.89M
Total Liabilities Q1 2022 · Dec 31, 2021 $81.75M
Current Assets Q1 2022 · Mar 31, 2022 $171.59M
Current Assets Q1 2022 · Dec 31, 2021 $174.27M
Total Assets Q1 2022 · Mar 31, 2022 $255.66M
Total Assets Q1 2022 · Dec 31, 2021 $257.51M
Eps Diluted Q1 2022 · Mar 31, 2022 −$0.01
Eps Diluted Q1 2022 · Mar 31, 2021 $0.02
Eps Basic Q1 2022 · Mar 31, 2022 −$0.01
Eps Basic Q1 2022 · Mar 31, 2021 $0.02
Sga Expense Q1 2022 · Mar 31, 2022 $20.6M
Sga Expense Q1 2022 · Mar 31, 2021 $17.61M
Rd Expense Q1 2022 · Mar 31, 2022 $5.01M
Rd Expense Q1 2022 · Mar 31, 2021 $2.64M
Net Income Q1 2022 · Mar 31, 2022 −$2.32M
Net Income Q1 2022 · Mar 31, 2021 $3.79M
Operating Income Q1 2022 · Mar 31, 2022 −$2.82M
Operating Income Q1 2022 · Mar 31, 2021 $5.39M
Revenue Q1 2022 · Mar 31, 2022 $41.56M
Revenue Q1 2022 · Mar 31, 2021 $42.08M